Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14608865 | 0.80 | CHRNA7 (0.32) | CHRNA7HTR3A | |
| SCHEMBL5229421 | 0.80 | CHRNA7 (0.37) | CHRNA7HTR3A | |
| SCHEMBL5228643 | 0.80 | CHRNA7 (0.52) | CHRNA7HTR3ASCN9A | |
| SCHEMBL5918030 | 0.79 | GABRP (0.45) | CHRNA7HTR3A | |
| SCHEMBL5918031 | 0.78 | SMYD3 (0.36) | CHRNA7HTR3ASCN9A | |
| SCHEMBL5226666 | 0.77 | CHRNA7 (0.55) | CHRNA7HTR3A | |
| SCHEMBL5918024 | 0.75 | CHRNA7 (0.54) | CHRNA7HTR3A | |
| SCHEMBL6007294 | 0.75 | CHRNA7 (0.54) | CHRNA7HTR3A | |
| SCHEMBL6098954 | 0.74 | CHRNB2 (0.36) | CHRNA7 | |
| SCHEMBL6101865 | 0.74 | CHRNB2 (0.36) | CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425286-B1 | SUBSTITUTED 7-AZA-[2.2.1]BICYCLOHEPTANES FOR THE TREATMENT OF DISEASES | PHARMACIA & UPJOHN CO LLC (US) | 2007-02-28 | — | — | EP | claimed |
| US-20060019984-A1 | Treatment of diseases with alpha-7nACh receptor full agonists | PFIZER INC | 2006-01-26 | — | — | US | claimed |
| US-20050245504-A1 | Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds | CORBETT JEFFREY W | 2005-11-03 | — | — | US | claimed |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | PFIZER INC | 2005-05-19 | — | — | US | claimed |
| US-20060019984-A1 | Treatment of diseases with alpha-7nACh receptor full agonists | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
| US-20050245504-A1 | Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds | CORBETT JEFFREY W | 2005-11-03 | — | — | US | disclosed |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | PFIZER INC | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245504-A1 | Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds | CHRNA7, CHRNG, CHRNE | CHRNA7 1/4885HTR3A 497/4885SCN9A 362/4885 |
| US-20060019984-A1 | Treatment of diseases with alpha-7nACh receptor full agonists | CHRNA7, CHRNA1, CHRNG | CHRNA7 1/4885HTR3A 426/4885SCN9A 401/4885 |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | CHRNA7, CHRNA10, SLC18A3 | CHRNA7 1/4885HTR3A 32/4885SCN9A 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.